Action NAVB NAVIDEA BIOPHARMACEUTICALS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Navidea Biopharmaceuticals, Inc.

Actions

NAVB

US63937X2027

Marché Fermé - OTC Markets
Autres places de cotation
 20:59:42 16/07/2024 		Varia. 5j. Varia. 1 janv.
0,001 USD -90,00 % Graphique intraday de Navidea Biopharmaceuticals, Inc. 0,00 % -98,19 %
03/07 Navidea Biopharmaceuticals, Inc. annonce les résultats d'une analyse exploratoire réalisée le 2 juillet 2024 CI
21/06 Navidea Biopharmaceuticals, Inc. annonce la démission de membres de son conseil d'administration CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Navidea Biopharmaceuticals, Inc. Announces Results of Exploratory Analysis Completed on July 2, 2024
Navidea Biopharmaceuticals, Inc. Announces Board Resignations
Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release
Navidea Biopharmaceuticals, Inc. announced that it has received $0.75 million in funding
Navidea: Q3 Earnings Snapshot
Navidea Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Navidea Biopharmaceuticals, Inc.(OTCPK:NAVB) dropped from S&P TMI Index
Sector Update: Health Care
Top Midday Decliners
Navidea Biopharmaceuticals Says NYSE American Panel Upheld Delisting Decision
Navidea Biopharmaceuticals, Inc. Announces NYSE American’s Decision to Suspend Trading In Its Common Stock
Navidea Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Navidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing Panel
Navidea Biopharmaceuticals, Inc. Announces Resignation of Malcolm G. Witter as Director, Member of the Audit Committee and Compensation, Nominating and Governance Committee of the Board
Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination
Navidea Biopharmaceuticals, Inc. Presses Ahead, Embraces Opportunities
Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination
Navidea Biopharmaceuticals, Inc. Announces Executive Changes
Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer
Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action NAVB
  4. Actualités Navidea Biopharmaceuticals, Inc.
  5. Autres langues